Literature DB >> 16543343

One-time general consent for research on biological samples: opt out system for patients is optimal and endorsed in many countries.

Jan Willem W Coebergh, Evert-Ben van Veen, Jan P Vandenbroucke, Paul van Diest, Wolter Oosterhuis.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16543343      PMCID： PMC1403227          DOI： 10.1136/bmj.332.7542.665

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

Review 1.  One-time general consent for research on biological samples.

Authors:  David Wendler
Journal:  BMJ       Date:  2006-03-04

Review 2.  Human genetic research: emerging trends in ethics.

Authors:  Bartha Maria Knoppers; Ruth Chadwick
Journal:  Nat Rev Genet       Date:  2005-01       Impact factor: 53.242

Review 3.  Tumour banks: well-guarded treasures in the interest of patients.

Authors:  J Wolter Oosterhuis; Jan Willem Coebergh; Evert-Ben van Veen
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716
  3 in total
  4 in total

1.  Inclusion of residual tissue in biobanks: opt-in or opt-out?

Authors:  Noor A A Giesbertz; Annelien L Bredenoord; Johannes J M van Delden
Journal:  PLoS Biol       Date:  2012-08-07       Impact factor: 8.029

2.  Molecular characterization of Barrett's esophagus at single-cell resolution.

Authors:  Georg A Busslinger; Buys de Barbanson; Rurika Oka; Bas L A Weusten; Michiel de Maat; Richard van Hillegersberg; Lodewijk A A Brosens; Ruben van Boxtel; Alexander van Oudenaarden; Hans Clevers
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

3.  A trial of consent procedures for future research with clinically derived biological samples.

Authors:  E Vermeulen; M K Schmidt; N K Aaronson; M Kuenen; M-J Baas-Vrancken Peeters; H van der Poel; S Horenblas; H Boot; V J Verwaal; A Cats; F E van Leeuwen
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

4.  Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

Authors:  Marjanka K Schmidt; Frans Hogervorst; Richard van Hien; Sten Cornelissen; Annegien Broeks; Muriel A Adank; Hanne Meijers; Quinten Waisfisz; Antoinette Hollestelle; Mieke Schutte; Ans van den Ouweland; Maartje Hooning; Irene L Andrulis; Hoda Anton-Culver; Natalia N Antonenkova; Antonis C Antoniou; Volker Arndt; Marina Bermisheva; Natalia V Bogdanova; Manjeet K Bolla; Hiltrud Brauch; Hermann Brenner; Thomas Brüning; Barbara Burwinkel; Jenny Chang-Claude; Georgia Chenevix-Trench; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Alison M Dunning; Peter A Fasching; Jonine Figueroa; Olivia Fletcher; Henrik Flyger; Eva Galle; Montserrat García-Closas; Graham G Giles; Lothar Haeberle; Per Hall; Peter Hillemanns; John L Hopper; Anna Jakubowska; Esther M John; Michael Jones; Elza Khusnutdinova; Julia A Knight; Veli-Matti Kosma; Vessela Kristensen; Andrew Lee; Annika Lindblom; Jan Lubinski; Arto Mannermaa; Sara Margolin; Alfons Meindl; Roger L Milne; Taru A Muranen; Polly A Newcomb; Kenneth Offit; Tjoung-Won Park-Simon; Julian Peto; Paul D P Pharoah; Mark Robson; Anja Rudolph; Elinor J Sawyer; Rita K Schmutzler; Caroline Seynaeve; Julie Soens; Melissa C Southey; Amanda B Spurdle; Harald Surowy; Anthony Swerdlow; Rob A E M Tollenaar; Ian Tomlinson; Amy Trentham-Dietz; Celine Vachon; Qin Wang; Alice S Whittemore; Argyrios Ziogas; Lizet van der Kolk; Heli Nevanlinna; Thilo Dörk; Stig Bojesen; Douglas F Easton
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.